A cohort study on the safety of bevacizumab in combination with neoadjuvant chemotherapy in the initial treatment of advanced ovarian cancer using a Japanese healthcare database
Not Applicable
- Conditions
- Advanced ovarian cancer
- Registration Number
- JPRN-UMIN000041175
- Lead Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Brief Summary
PTX+CBDCA (TC) was most commonly used as first-line treatment. TC+Bev was used in 9.3% and 11.6% of patients in the NAC and PDS groups, respectively. The proportion of patients with risk factors for GI perforation in the TC+Bev group of NAC was lower compared to patients without Bev. The incidence of GI perforation in the NAC group was 0.38% in patients receiving TC+Bev and 0.18% in patients receiving TC without Bev (risk ratio=2.13; 95%CI=0.19 to 23.36; risk difference=0.20; 95%CI=-0.58 to 0.97).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 7839
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with cancer other than ovarian cancer, fallopian tube cancer or peritoneal cancer
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method